CD52 and toxoplasmosis: Identified toxoplasmosis cases were associated with the following classes of biologic agents: (a) tumor necrosis factor-a inhibitors (anti-TNF-a) (n = 18), (b) T-cell co-stimulation inhibitors (n = 3), (c) anti-CD20 (n = 5), (d) anti-CD52 (n = 4), (e) CAR-T-cell therapies (n = 3), (f) IL-12/IL-23 inhibitor (n = 2); (g) interleukin-17 (IL-17-a) inhibitor (n = 1), (h) anti-CD40 (n = 1), and (i) cell adhesion molecule inhibitors/integrin receptor inhibitors (n = 1).